Amarin Corp (NASDAQ: AMRN) released first quarter 2012 financial results and held a conference call on May 8, 2012. It is often hard to distinguish the signal from the noise when it comes to chatter about AMRN on Twitter and other venues, so we will try to objectively update where things stand as the July […]
AMLN – Neutral/Bearish Trade for PDUFA
Analyst Notes: These kind of things are troubling because of the cardiovascular nature of the FDA’s qualms. However, give it a 50% success probability “In the second CRL, Amylin and its partners were asked to conduct a thorough QT (tQT) study with Bydureon and submit data from the DURATION-5 study which was conducted to compare […]
